XLONROQ
Market cap6mUSD
Dec 24, Last price
4.05GBP
1D
2.53%
1Q
12.50%
IPO
-99.51%
Name
Roquefort Therapeutics PLC
Chart & Performance
P/E
—
P/S
2,748.67
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
200k
Net income
-2m
L+7.99%
CFO
-2m
L+9.89%
Earnings
Apr 24, 2025
Profile
Roquefort Therapeutics plc operates as a biotechnology research company. The company engages in the research and development of drugs targeting Midkine, a circulating growth factor protein and pro-inflammatory mediator for the treatment of cancer. Roquefort Therapeutics plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY |
|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | |
| Income | |||
Revenues | 200 | 719 | |
Cost of revenue | 2,130 | 1,260 | 511 |
Unusual Expense (Income) | |||
NOPBT | (1,930) | (1,260) | (511) |
NOPBT Margin | |||
Operating Taxes | (188) | (19) | (201) |
Tax Rate | |||
NOPAT | (1,742) | (1,241) | (310) |
Net income | (1,745) 7.99% | (1,615) 76.08% | (917) |
Dividends | |||
Dividend yield | |||
Proceeds from repurchase of equity | 3,121 | 4,630 | |
BB yield | |||
| Debt | |||
Debt current | |||
Long-term debt | |||
Deferred revenue | |||
Other long-term liabilities | |||
Net debt | (537) | (2,323) | (900) |
| Cash flow | |||
Cash from operating activities | (1,734) | (1,577) | (2,623) |
CAPEX | (54) | ||
Cash from investing activities | (53) | (103) | (1,106) |
Cash from financing activities | (58) | 3,102 | 4,630 |
FCF | (1,792) | 742 | |
| Balance | |||
Cash | 537 | 2,323 | 900 |
Long term investments | |||
Excess cash | 527 | 2,323 | 900 |
Stockholders' equity | 1,096 | (896) | 172 |
Invested Capital | 4,972 | 8,103 | 3,911 |
ROIC | |||
ROCE | |||
| EV | |||
Common stock shares outstanding | 129,150 | 103,479 | 24,702 |
Price | |||
Market cap | |||
EV | |||
EBITDA | (1,926) | (1,260) | (511) |
EV/EBITDA | |||
Interest | 58 | ||
Interest/NOPBT | |||